General Information of Drug Transporter (DT)
DT ID DTD0003 Transporter Info
Gene Name ABCB1
Protein Name P-glycoprotein 1
Gene ID
5243
UniProt ID
P08183
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism rs1045642
Site of GPD chr7:87509329 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP A>G / A>T
Minor Allele Frequency A=0.3952/1979 (Global)
Allele A
Methadone Drug Info Opioid-Related Disorders Correlated with the decreased drug concentrations in patients (compare with allele G) [1]
Vincristine Drug Info Precursor Cell Lymphoblastic Leukemia-Lymphoma Correlated with the decreased likelihood of event-free survival in patients (compare with allele G) [2]
Simvastatin Drug Info Hypercholesterolemia Correlated with the decreased myalgia risk in patients (compare with allele G) [3]
Nelfinavir Drug Info HIV Infection Correlated with the decreased toxic liver disease risk in patient (compare with allele G); Correlated with the increased likelihood of toxicity-related treatment failure in patients (compare with allele G) [4], [5]
Methotrexate Drug Info Rheumatoid Arthritis Correlated with the increased adverse drug event risk in patients (compare with allele G); Irrelevant to the drug discontinuation in patients (compare with allele G); Irrelevant to the drug response in patients (compare with Allele G) [6], [7], [8]
Clopidogrel Drug Info Hemorrhage Correlated with the increased disease risk in patients (compare with allele G) [9]
Clopidogrel Drug Info Acute Coronary Syndrome Correlated with the increased disease risk in patients (compare with allele G); Irrelevant to the drug exposure in patients (compare with allele G); Irrelevant to the the drug antiplatelet effect or clinical outcomes in patients (compare with Allele G) [10], [11], [12]
Digoxin Drug Info Congestive Cardiac Insufficiency; Arrhythmias; Heart Failure Correlated with the increased drug serum concentrations in patients (compare with allele G) [13]
Codeine Drug Info CNS Depression Correlated with the increased likelihood of disease in patients (compare with allele G) [14]
Carbamazepine Drug Info Epilepsy Correlated with the increased likelihood of drug resistance in patients (compare with allele G); Irrelevant to the drug concentrations in patients (compare with allele G); Irrelevant to the drug metabolism in patients (compare with Allele G); Irrelevant to the increased drug response in patients (compare with Allele G) [15], [16], [17], [18]
Everolimus Drug Info Breast Neoplasm Correlated with the increased likelihood of mucositis in patients (compare with allele G) [19]
Atorvastatin Drug Info Coronary Artery Disease Correlated with the increased likelihood of myalgia in patients (compare with allele G) [20]
Phenytoin Drug Info Healthy Individuals Correlated with the increased plasma drug levels in healthy individuals (compare with genotype GG) [21]
Olanzapine Drug Info Psychotic Disorders Correlated with the positive relationship between drug plasma levels and positive symptom reduction in patients (compare genotype GG) [22]
Tacrolimus Drug Info Kidney Transplantation Irrelevant to the acute cellular rejection in patients (compare with allele G); Irrelevant to the dose-adjusted trough concentrations in patients (compare with allele G); Irrelevant to the drug bioavailability in patients (compare with allele G); Irrelevant to the drug clearance in patients (compare with Allele G); Irrelevant to the drug clearance in patients (compare with allele G); Irrelevant to the drug metabolism in patients (compare with Allele G); Irrelevant to the drug trough concentrations in patients (compare with Allele G); Irrelevant to the likelihood of achieving target concentrations of drug in patients (compare with Allele G) [23], [24], [25], [26], [27], [28], [29], [30], [31], [32]
Paliperidone Drug Info Bipolar Disorder Irrelevant to the drug clearance in patients (compare with Allele A) [33]
Paliperidone Drug Info Psychotic Disorders Irrelevant to the drug clearance in patients (compare with Allele A) [34]
Risperidone Drug Info Bipolar Disorder Irrelevant to the drug clearance in patients (compare with Allele A) [33]
Risperidone Drug Info Psychotic Disorders Irrelevant to the drug clearance in patients (compare with Allele A) [34]
Tacrolimus Drug Info Hemopoietic Stem Cell Transplant Irrelevant to the drug clearance in patients (compare with Allele G) [35]
Tacrolimus Drug Info Liver Transplantation Irrelevant to the drug clearance in patients (compare with Allele G) [36]
Cyclosporine Drug Info Kidney Transplantation Irrelevant to the drug clearance in patients (compare with allele G) [23]
Sirolimus Drug Info Kidney Transplantation Irrelevant to the drug metabolism in patients (compare with Allele G) [24]
Imatinib Drug Info Bcr-Abl Positive Chronic Myelogenous Leukemia Irrelevant to the drug response in patients (compare with Allele G) [37]
Methotrexate Drug Info Precursor Cell Lymphoblastic Leukemia-Lymphoma Irrelevant to the drug response in patients (compare with Allele G) [38]
Clopidogrel Drug Info Angina Pectoris Irrelevant to the drug response in patients (compare with Allele G) [39]
Clopidogrel Drug Info Platelet Reactivity Irrelevant to the drug response in patients (compare with Allele G); Irrelevant to the the antiplatelet effect or drug clinical outcomes in patients (compare with Allele G) [12], [40]
Sunitinib Drug Info Renal Cell Carcinoma Irrelevant to the drug toxicity in patients (compare with allele G) [41]
Clopidogrel Drug Info St-Segment Elevation Myocardial Infarction Irrelevant to the increased disease risk in patients (compare with allele G) [42]
Valproic acid Drug Info Epilepsy Irrelevant to the increased drug response in patients (compare with Allele G) [15]
Phenytoin Drug Info Epilepsy Irrelevant to the increased drug response in patients (compare with Allele G) [15]
Phenobarbital Drug Info Epilepsy Irrelevant to the increased drug response in patients (compare with Allele G) [15]
Clopidogrel Drug Info Coronary Artery Disease Irrelevant to the increased high on-treatment platelet reactivity risk in patients (compare with Allele G); Irrelevant to the increased myocardial infarction (mI) or composite outcome of non-fatal mI, all cause death and stent thrombosis risk in patients (compare with Allele G); Irrelevant to the major adverse cardiac risk in patients (compare with Allele G) [43], [44], [45]
Clopidogrel Drug Info Percutaneous Coronary Intervention Irrelevant to the increased high post-treatment platelet reactivity risk in patients (compare with Allele G) [46]
Clopidogrel Drug Info Myocardial Infarction Irrelevant to the increased mortality risk in patients (compare with Allele G) [47]
Clopidogrel Drug Info Coronary Disease Irrelevant to the increased on-treatment platelet activity risk in patients (compare with Allele G) [48]
Ritonavir Drug Info HIV Infection Irrelevant to the likelihood of treatment failure in patients (compare with Allele G) [49]
Ranitidine Drug Info Breast Neoplasm Irrelevant to the overall survival in patients (compare with Allele G) [50]
Dexamethasone Drug Info Breast Neoplasm Irrelevant to the overall survival in patients (compare with Allele G) [50]
Paclitaxel Drug Info Breast Neoplasm Irrelevant to the overall survival in patients (compare with Allele G) [50]
Oxcarbazepine Drug Info Epilepsy Correlated with the decreased drug response in patients (compare with allele G) [51]
Nevirapine Drug Info HIV Infection Correlated with the decreased toxic liver disease risk in patients (compare with allele G); Correlated with the decreased toxic liver disease risk in patients (compare with allele G) [5], [52], [53]
Isoniazid Drug Info Tuberculosis Irrelevant to the drug-induced liver injury risk in patients (compare with Allele G) [54]
Atazanavir Drug Info HIV Infection Irrelevant to the likelihood of treatment failure in patients (compare with Allele G) [49]
Efavirenz Drug Info HIV Infection Correlated with the decreased toxic liver disease risk in patient (compare with allele G); Correlated with the decreased toxic liver disease risk in patients (compare with allele G); Correlated with the increased likelihood of toxicity-related treatment failure in patients (compare with allele G) [4], [5]
Oxycodone Drug Info Postoperative Pain Irrelevant to the severity of pain in patients (compare with Allele G) [55]
Diphenhydramine Drug Info Breast Neoplasm Irrelevant to the overall survival in patients (compare with Allele G) [50]
Allele G
Phenytoin Drug Info Epilepsy Correlated with the increased likelihood of drug resistance in patients (compare with Allele A); Irrelevant to the drug response in patients (compare with allele A) [56], [57]
Atorvastatin Drug Info Coronary Artery Disease Irrelevant to the dose decrease or drug switching risk (compare with allele A) [58]
Atorvastatin Drug Info Hypercholesterolemia Irrelevant to the dose decrease or drug switching risk (compare with allele A) [58]
Simvastatin Drug Info Coronary Artery Disease Irrelevant to the dose decrease or drug switching risk (compare with allele A) [58]
Simvastatin Drug Info Hypercholesterolemia Irrelevant to the dose decrease or drug switching risk (compare with allele A) [58]
Tacrolimus Drug Info Organ Transplantation Irrelevant to the drug concentrations in patients (compare with Allele A) [59]
Tacrolimus Drug Info Kidney Transplantation Irrelevant to the drug metabolism in patients (compare with allele A) [60]
Methotrexate Drug Info Rheumatoid Arthritis Irrelevant to the drug response in patients (compare with allele A) [61]
Fluorouracil Drug Info Esophageal Neoplasm Irrelevant to the drug response in patients (compare with allele A) [62]
Clopidogrel Drug Info Acute Coronary Syndrome Irrelevant to the drug response in patients (compare with allele A) [63]
Clopidogrel Drug Info Myocardial Infarction Irrelevant to the drug response in patients (compare with allele A) [64]
Cisplatin Drug Info Esophageal Neoplasm Irrelevant to the drug response in patients (compare with allele A) [62]
Carbamazepine Drug Info Epilepsy Irrelevant to the drug response in patients (compare with allele A) [56]
Valproic acid Drug Info Epilepsy Irrelevant to the drug response in patients (compare with allele A) [56]
Phenobarbital Drug Info Epilepsy Irrelevant to the drug response in patients (compare with allele A) [56]
Ritonavir Drug Info HIV Infection Irrelevant to the hyperbilirubinemia risk in patients (compare with allele A); Irrelevant to the severity of hyperbilirubinemia in patients (compare with allele A); Irrelevant to the trough concentration of drug in patients (compare with allele A) [65], [66], [67]
Paliperidone Drug Info Schizophrenia Irrelevant to the increased drug metabolism in patients (compare with Allele A) [68]
Risperidone Drug Info Schizophrenia Irrelevant to the increased drug metabolism in patients (compare with Allele A) [68]
Fluorouracil Drug Info Breast Neoplasm Irrelevant to the likelihood of drug toxicity in patients (compare with allele A) [69]
Cyclophosphamide Drug Info Breast Neoplasm Irrelevant to the likelihood of drug toxicity in patients (compare with allele A) [69]
Atazanavir Drug Info HIV Infection Irrelevant to the drug concentrations in patients (compare with Allele A); Irrelevant to the hyperbilirubinemia risk in patients (compare with allele A); Irrelevant to the likelihood of hyperbilirubinemia in patients (compare with allele A); Irrelevant to the severity of hyperbilirubinemia in patients (compare with allele A); Irrelevant to the trough concentration of drug in patients (compare with allele A) [65], [66], [67], [70]
Efavirenz Drug Info HIV Infection Irrelevant to the neurotoxicity syndromes in patients (compare with allele A) [71]
Antiepileptics N.A. Epilepsy Irrelevant to the drug resistance in patients (compare with allele A); Irrelevant to the drug response in patients (compare with allele A) [72], [73], [74], [75]
Genotype AA
Clopidogrel Drug Info Coronary Artery Disease Correlated with the decreased bleeding events in patients (compare with genotype GG); Correlated with the decreased drug exposure in patients (compare with genotypes AG + GG); Correlated with the decreased drug peak plasma concentration (Cmax) and the total area under the plasma concentration-time curve (AUC) in patients (compare with genotypes GG + AG); Correlated with the decreased drug response in patients (compare with genotypes AG + GG); Correlated with the increase early major adverse cardiovascular events (mACE) risk in patients (compare with genotype GG) [76], [77], [78], [79]
Tacrolimus Drug Info Kidney Transplantation Correlated with the decreased drug clearance in patients (compare with genotypes AG + GG); Correlated with the decreased drug metabolism in patients (compare with genotype GG); Correlated with the increased drug dose in patients (compare with genotype AG) [80], [81], [82]
Digoxin Drug Info Congestive Cardiac Insufficiency; Arrhythmias; Heart Failure Correlated with the decreased drug metabolism (compare with genotype GG) [83]
Fexofenadine Drug Info Healthy Individuals Correlated with the decreased drug plasma concentration in healthy individuals (compare with genotypes GG + AG) [84]
Fentanyl Drug Info Neoplasm Correlated with the decreased drug response in patients (compare with Genotype AA + AG) [85]
Methotrexate Drug Info Rheumatoid Arthritis Correlated with the decreased drug response in patients (compare with genotypes AG + GG) [86]
Anastrozole Drug Info Breast Neoplasm Correlated with the decreased likelihood of Arthralgia in patients (compare with genotypes AG + GG) [87]
Pantoprazole Drug Info Helicobacter Infections Correlated with the decreased likelihood of Postoperative nausea and Vomiting in patients (compare with genotypes AG + GG); Correlated with the increased drug response in patients (compare with genotypes AG + GG) [88], [89]
Sunitinib Drug Info Renal Cell Carcinoma Correlated with the decreased neutropenia risk in patients (compare with genotypes AG + GG) [90]
Methylprednisolone Drug Info Kidney Transplantation Correlated with the decreased osteonecrosis risk in patients (compare with genotypes GG + AG) [80]
Prednisolone Drug Info Kidney Transplantation Correlated with the decreased osteonecrosis risk in patients (compare with genotypes GG + AG) [80]
Clozapine Drug Info Schizophrenia Correlated with the increased agranulocytosis and neutropenia risk in patients (compare with genotypes AG + GG); Correlated with the increased drug plasma concentrations in patients (compare with genotype GG) [91], [92]
Vincristine Drug Info Lymphoma Correlated with the increased anemia and thrombocytopenia risk in patients (compare with genotypes AG + GG) [93]
Doxorubicin Drug Info Lymphoma Correlated with the increased anemia and thrombocytopenia risk in patients (compare with genotypes AG + GG) [93]
Prednisolone Drug Info Lymphoma Correlated with the increased anemia and thrombocytopenia risk in patients (compare with genotypes AG + GG) [93]
Methotrexate Drug Info Lymphoma Correlated with the increased anemia and thrombocytopenia risk in patients (compare with genotypes AG + GG); Correlated with the increased drug concentrations in patients (compare with genotype GG); Correlated with the increased toxic liver disease risk in patients (compare with genotype GG) [93], [94]
Clopidogrel Drug Info Acute Coronary Syndrome Correlated with the increased cardiovascular death, myocardial infarction, or stroke risk in patients (compare with genotypes GG + AG); Correlated with the increased thrombosis risk in pstients(compare with genotypes AG + GG) [95], [96]
Clopidogrel Drug Info Myocardial Infarction Correlated with the increased cardiovascular events risk in patients (compare with genotype GG); Correlated with the increased platelet reactivity in patients (compare with genotypes AG + GG) [97], [98]
Nelfinavir Drug Info HIV Infection Correlated with the increased CD4 t cell count in patients (compare with genotype AG + GG) [99]
Tacrolimus Drug Info Rheumatoid Arthritis Correlated with the increased dose-adjusted trough concentrations in patients (compare with genotype GG) [100]
Talinolol Drug Info Healthy Individuals Correlated with the increased drug clearance in healthy individuals (compare with genotypes AG + GG) [101]
Methadone Drug Info Opioid-Related Disorders Correlated with the increased drug clearance in patients (compare with genotypes AG + GG) [102]
Methadone Drug Info Heroin Dependence Correlated with the increased drug dose in patients (compare with genotype GG) [103]
Tramadol Drug Info Pain Correlated with the increased drug exposure (compare with genotype GG) [104]
Morphine Drug Info Pain Correlated with the increased drug metabolism in patients (compare with genotypes AG + GG) [105]
Imatinib Drug Info Bcr-Abl Positive Chronic Myelogenous Leukemia Correlated with the increased drug response in patients (compare with genotypes AG + GG) [106]
Fentanyl Drug Info Postoperative Pain Correlated with the increased likelihood of respiratory insufficiency in patients (compare with Genotype AA + AG) [107]
Morphine Drug Info Neoplasm Correlated with the increased reduction in pain in patients (compare with genotypes AG + GG) [108]
Simvastatin Drug Info Coronary Artery Disease Correlated with the increased reduction in total cholesterol in patients (compare with genotype GG) [109]
Tacrolimus Drug Info Liver Transplantation Irrelevant to the drug concentrations in patients (compare with genotypes AG + GG) [110]
Daunorubicin Drug Info Acute Myeloid Leukemia Irrelevant to the drug response in patients (compare with genotypes AG + GG) [111]
Cytarabine Drug Info Acute Myeloid Leukemia Irrelevant to the drug response in patients (compare with genotypes AG + GG) [111]
Methotrexate Drug Info Hematologic Neoplasm Irrelevant to the neurotoxicity syndromes risk in patients (compare with genotypes AG + GG) [112]
Voriconazole Drug Info Healthy Individuals Correlated with the decreased drug metabolism in healthy individuals (compare with genotype GG) [113]
Granisetron Drug Info Nausea; Vomiting Correlated with the increased drug response in patients (compare with genotypes AG + GG) [114]
Dexrazoxane Drug Info Acute Myeloid Leukemia Irrelevant to the drug response in patients (compare with genotypes AG + GG) [111]
Efavirenz Drug Info HIV Infection Correlated with the decreased drug concentrations in patients (compare with genotypes AG + GG); Correlated with the increased CD4 t cell count in patients (compare with genotype AG + GG); Correlated with the increased CD4 t cell count in patients (compare with genotype GG); Correlated with the increased drug clearance in patients (compare with genotype AG); Correlated with the increased likelihood of drug responses in patients (compare with genotypes GG + Gt); Irrelevant to increased likelihood of drug plasma exposure in patients (compare with genotypes AG + GG) [4], [99], [115], [117]
Daptomycin Drug Info Bacterial infections Correlated with the decreased drug clearance in patients (compare with genotypes AG + GG); Correlated with the increased drug concentrations in patients (compare with genotypes AG + GG) [118]
Nortriptyline Drug Info Major Depressive Disorder Correlated with the increased likelihood of hypotension, orthostatic in patients (compare with genotypes AG + GG) [119]
Palonosetron Drug Info Nausea; Vomiting Irrelevant to the drug response in patients (compare with genotypes AG + GG) [120]
Omeprazole Drug Info Helicobacter Infections Correlated with the decreased likelihood of postoperative nausea and vomiting in patients (compare with genotypes AG + GG); Correlated with the increased drug response in patients (compare with genotypes AG + GG) [88], [89]
Opioids N.A. Neoplasm Correlated with the decreased drug dose in patients (compare with genotypes AG + GG) [121]
Opioids N.A. Postoperative Pain Correlated with the decreased drug dose in patients (compare with genotypes AG + GG) [122]
Antiepileptics N.A. Epilepsy Correlated with the increased drug resistance in patients (compare with genotype GG) [123], [124]
Antivirals combinations drugs for treatment of tuberculosis N.A. HIV Infection; Tuberculosis Co-Infection Correlated with the increased drug-induced liver injury risk in patieants (compare with genotype GG) [125]
Anthracyclines N.A. Breast Neoplasm Correlated with the increased likelihood of complete response in patients (compare with genotypes GG + AG) [126]
Taxanes N.A. Breast Neoplasm Correlated with the increased likelihood of complete response in patients (compare with genotypes GG + AG) [126]
Genotype AG
Paclitaxel Drug Info Breast Neoplasm Correlated with the decreased disease control rate and lower overall survival rate in patients (compare with genotype GG) [126]
Methotrexate Drug Info Rheumatoid Arthritis Correlated with the decreased drug toxicity risk in patients (compare with genotype GG) [127]
Tamoxifen Drug Info Breast Neoplasm Correlated with the increased disease recurrence risk in patients (compare with genotype GG); Correlated with the increased disease recurrence risk in patients (compare with genotypes AA + GG) [128]
Methadone Drug Info Opioid-Related Disorders Correlated with the increased drug concentrations in patients (compare with genotypes AA + GG) [129]
Tacrolimus Drug Info Kidney Transplantation Correlated with the increased hypokalemia risk in patients (compare with genotypes AA + GG); Correlated with the increased transplant rejection risk in patients (compare with genotypes AA + GG); Irrelevant to the drug concentrations in patients (compare with genotype GG) [32], [131]
Oxaliplatin Drug Info Colorectal Neoplasm Correlated with the increased recurrence-free survival in patients (compare with genotype AA) [132]
Carbamazepine Drug Info Epilepsy Irrelevant to the drug metabolism in patients (compare with genotypes AA + GG) [133]
Modafinil Drug Info Narcolepsy Correlated with the increased drug response in patients (compare with genotypes AA + GG) [134]
Antiepileptics N.A. Epilepsy Correlated with the increased drug resistance in patients (compare with genotype GG) [122]
Antineoplastic agents N.A. Neoplasm Correlated with the increased severity of nausea in patients (compare with genotypes AA + GG) [136]
Genotype GA
Methotrexate Drug Info Rheumatoid Arthritis Correlated with the increased nonresponse risk in patients [135]
Genotype GG
Fluorouracil Drug Info Colorectal Neoplasm Correlated with the decreased diarrhea risk in patients (compare with genotype AA); Irrelevant to the drug response in patients (compare with genotypes AA + AG); Irrelevant to the drug toxicity in patients (compare with genotypes AA + AG) [136], [137]
Cyclosporine Drug Info Transplantation Correlated with the decreased drug concentrations in patients (compare with genotype AA); Correlated with the decreased drug intracellular and blood concentration in patients (compare with genotypes AA + AG) [138], [139]
Verapamil Drug Info Healthy Individuals Correlated with the decreased drug metabolism in healthy individuals (compare with genotypes AA + AG) [140]
Atorvastatin Drug Info Coronary Artery Disease Correlated with the decreased drug response in patients (compare with genotypes AA + AG); Irrelevant to the drug response in patients (compare with genotype AA) [20], [141]
Vincristine Drug Info Multiple Myeloma Correlated with the decreased survival in patients (compare with genotype AA) [143]
Dexamethasone Drug Info Multiple Myeloma Correlated with the decreased survival in patients (compare with genotype AA) [143]
Doxorubicin Drug Info Multiple Myeloma Correlated with the decreased survival in patients (compare with genotype AA) [143]
Fluorouracil Drug Info Esophageal Neoplasm Correlated with the decreased survival rate in patients (compare with genotypes AA + AG) [62]
Cisplatin Drug Info Esophageal Neoplasm Correlated with the decreased survival rate in patients (compare with genotypes AA + AG) [62]
Fluorouracil Drug Info Breast Neoplasm Correlated with the increased anemia risk in patients (compare with genotypes AA + AG) [145]
Doxorubicin Drug Info Breast Neoplasm Correlated with the increased anemia risk in patients (compare with genotypes AA + AG) [145]
Cyclophosphamide Drug Info Breast Neoplasm Correlated with the increased anemia risk in patients (compare with genotypes AA + AG) [145]
Probenecid Drug Info Gout; Hyperuricemia Correlated with the increased drug clearance (compare with genotype AG) [146]
Dicloxacillin Drug Info Cystic Fibrosis Correlated with the increased drug clearance (compare with genotype AG) [146]
Carbamazepine Drug Info Epilepsy Correlated with the increased drug concentrations in patients (compare with genotype AG); Irrelevant to the drug resistance in patients (compare with genotypes AA + AG) [132], [148]
Paliperidone Drug Info Healthy Individuals Correlated with the increased drug exposure in healthy individuals (compare with Genotypes AA + AG) [149]
Risperidone Drug Info Healthy Individuals Correlated with the increased drug exposure in healthy individuals (compare with Genotypes AA + AG) [149]
Digoxin Drug Info Congestive Cardiac Insufficiency; Arrhythmias; Heart Failure Correlated with the increased drug metabolism (compare with genotype AA) [150]
Etoposide Drug Info Precursor Cell Lymphoblastic Leukemia-Lymphoma Correlated with the increased drug metabolism in patients (compare with genotypes AA + AG) [151]
Tacrolimus Drug Info Liver Transplantation Correlated with the increased drug metabolism in patients (compare with genotypes AA + AG); Irrelevant to the drug dose-adjusted trough concentrations in patients (compare with genotypes AA + AG); Irrelevant to the drug metabolism in patients (compare with genotypes AA + AG) [152], [153], [154]
Clopidogrel Drug Info Hypertension Correlated with the increased drug resistance in patients (compare with genotype AA) [155]
Phenobarbital Drug Info Epilepsy Correlated with the increased drug resistance in patients (compare with genotype AA) [156]
Imatinib Drug Info Bcr-Abl Positive Chronic Myelogenous Leukemia Correlated with the increased drug response in patients (compare with genotypes AA + AG); Irrelevant to the drug response in patients (compare with genotypes AA + AG) [157], [158]
Methotrexate Drug Info Rheumatoid Arthritis Correlated with the increased drug toxicity risk in patients (compare with genotypes AA + AG) [159]
Sunitinib Drug Info Renal Cell Carcinoma Correlated with the increased exanthema and mucositis risk in patients (compare with genotypes AA + AG) [160]
Clopidogrel Drug Info Acute Coronary Syndrome Correlated with the increased ischaemic events risk in patients (compare with genotypes AA + AG) [161]
Cytarabine Drug Info Acute Myeloid Leukemia Correlated with the increased likelihood of 3-year Event Free Survival in patients (compare with genotypes AA + AG); Correlated with the increased likelihood of complete remission in patients (compare with genotypes AA + AG) [162]
Cytarabine Drug Info Acute Multiple Myeloma Irrelevant to the decreased survival in patients (compare with genotype AA) [163]
Tacrolimus Drug Info Kidney Transplantation Irrelevant to the drug clearance in patients (compare with genotypes AA + AG); Irrelevant to the drug dose-adjusted trough concentrations in patients (compare with Allele T); Irrelevant to the drug dose-adjusted trough concentrations in patients (compare with genotypes AA + AG); Irrelevant to the drug metabolism in patients (compare with genotypes AA + AG); Irrelevant to the glomerular filtration rate in patients (compare with genotypes AA + AG) [164], [165], [166], [167], [168]
Bilirubin Drug Info HIV Infection Irrelevant to the drug concentrations in patients (compare with genotypes AA + AG) [169]
Tacrolimus Drug Info Organ Transplantation Irrelevant to the drug concentrations in patients (compare with genotypes AA + AG) [170]
Tacrolimus Drug Info Rheumatoid Arthritis Irrelevant to the drug dose-adjusted trough concentrations in patients (compare with genotypes AA + AG) [171]
Simvastatin Drug Info Hypercholesterolemia Irrelevant to the drug response in patients (compare with genotypes AA + AG) [3]
Irinotecan Drug Info Colorectal Neoplasm Irrelevant to the drug response in patients (compare with genotypes AA + AG); Irrelevant to the drug toxicity in patients (compare with genotypes AA + AG) [137]
Oxaliplatin Drug Info Colorectal Neoplasm Irrelevant to the drug response in patients (compare with genotypes AA + AG); Irrelevant to the drug toxicity in patients (compare with genotypes AA + AG) [137]
Agomelatine Drug Info Depressive Disorder Correlated with the increased drug response in patients (compare with genotypes AA + AG) [173]
Oxcarbazepine Drug Info Epilepsy Correlated with the increased drug concentrations in patients (compare with genotypes AA + AG) [51]
Venlafaxine Drug Info Depressive Disorder Correlated with the increased drug response in patients (compare with genotypes AA + AG) [173]
Venlafaxine Drug Info Narcolepsy Irrelevant to the drug response in patients (compare with genotypes AA + AG) [133]
Nevirapine Drug Info HIV Infection Irrelevant to the drug metabolism in patients (compare with genotype AA) [176]
Atazanavir Drug Info HIV Infection Correlated with the increased drug concentrations in patients (compare with genotypes AA + AG); Irrelevant to the drug concentrations in patients (compare with genotypes AA + AG) [169], [66]
Efavirenz Drug Info HIV Infection Correlated with the decreased drug clearance in patients (compare with genotype AG); Irrelevant to the drug metabolism in patients (compare with genotype AA) [176], [116]
Silibinin Drug Info Healthy Individuals Correlated with the increased drug exposure in healthy individuals (compare with genotype AA) [179]
Idarubicin Drug Info Acute Myeloid Leukemia Correlated with the increased likelihood of 3-year Event Free Survival in patients (compare with genotypes AA + AG); Correlated with the increased likelihood of complete remission in patients (compare with genotypes AA + AG) [162]
Capecitabine Drug Info Colorectal Neoplasm Correlated with the increased hand-foot syndrome risk in patients (compare with genotype AA) [136]
Opioids N.A. Opioid-Related Disorders Correlated with the decreased opioid-related disorders risk in patients (compare with genotype AG) [180]
Melatonin receptor agonists N.A. Depressive Disorder Correlated with the increased drug response in patients (compare with genotypes AA + AG) [173]
Platinum compounds N.A. Non-Small-Cell Lung Carcinoma Correlated with the increased drug response in patients (compare with genotypes AA + AG) [181]
Selective serotonin reuptake inhibitors N.A. Depressive Disorder Correlated with the increased drug response in patients (compare with genotypes AA + AG) [173]
Antiepileptics N.A. Epilepsy Correlated with the increased likelihood of drug-resistance in patients (compare with genotype AA) [182]
Genotypes AA + AG
Clopidogrel Drug Info Acute Coronary Syndrome Correlated with the decreased drug metabolism in patients (compare with genotype GG); Correlated with the decreased drug response in patients (compare with genotype GG); Correlated with the increased early major adverse cardiovascular events (mACE) risk in patients (compare with genotype GG); Irrelevant to the drug response in patients (compare with genotype GG); Irrelevant to the increased high on-treatment platelet reactivity risk in patients (compare with genotype GG) [77], [175], [177], [178], [179]
Clopidogrel Drug Info Platelet Reactivity Correlated with the decreased drug response in patients (compare with genotype GG) [175]
Imatinib Drug Info Bcr-Abl Positive Chronic Myelogenous Leukemia Correlated with the decreased drug response in patients (compare with genotype GG); Correlated with the decreased drug trough concentration in patients (compare with genotype GG) [154], [181]
Tacrolimus Drug Info Kidney Transplantation Correlated with the decreased glomerular filtration rate in patients (compare with genotype GG); Irrelevant to the drug dose-adjusted trough concentrations in patients (compare with genotype GG); Irrelevant to the renal transplant failure risk in patients (compare with genotype GG); Irrelevant to the transplant rejection risk in patients (compare with genotype GG) [182], [163], [184]
Fluorouracil Drug Info Esophageal Neoplasm Correlated with the decreased lymph node metastases risk in patients (compare with genotype GG) [62]
Cisplatin Drug Info Esophageal Neoplasm Correlated with the decreased lymph node metastases risk in patients (compare with genotype GG) [62]
Tacrolimus Drug Info Lung Transplantation Correlated with the increased drug concentrations in patients (compare with genotype GG) [186]
Rivaroxaban Drug Info Healthy Individuals Correlated with the increased drug exposure in healthy individuals (compare with genotype GG) [187]
Dabigatran Drug Info Healthy Individuals Correlated with the increased drug exposure in healthy individuals (compare with genotype GG) [187]
Losartan Drug Info Hypertension Correlated with the increased drug response in patients (compare with genotype GG) [188]
Methotrexate Drug Info Precursor Cell Lymphoblastic Leukemia-Lymphoma Correlated with the increased drug toxicity risk in patients (compare with genotype GG); Irrelevant to the drug concentrations in patients (compare with genotype GG); Irrelevant to the mucositis risk in patients (compare with genotype GG) [38], [190]
Sorafenib Drug Info Renal Cell Carcinoma Correlated with the increased hypertension risk in patients (compare with genotype GG) [191]
Sirolimus Drug Info Kidney Transplantation Correlated with the increased low-density lipoprotein cholesterol in patients (compare with genotype GG); Correlated with the increased total cholesterol in patients (compare with genotype GG) [192]
Clopidogrel Drug Info Coronary Artery Disease Correlated with the increased major adverse cardiovascular events (mACE) risk in patients (compare with genotype GG); Irrelevant to the all-cause mortality in patients (compare with genotype GG); Irrelevant to the increased high on-treatment platelet reactivity risk in patients (compare with genotype GG); Irrelevant to the increased ischemic stroke risk in patients (compare with genotype GG); Irrelevant to the increased major adverse cardiovascular events (MACE) risk in patients (compare with genotype GG); Irrelevant to the increased myocardial Infarction risk in patients (compare with genotype GG); Irrelevant to the stent thrombosis in patients (compare with genotype GG) [77]
Clopidogrel Drug Info Myocardial Infarction Correlated with the increased major cardiovascular events (mACE) risk in patients (compare with genotype GG) [193]
Cytarabine Drug Info Acute Multiple Myeloma Correlated with the increased overall survival in patients (compare with genotype GG) [194]
Ritonavir Drug Info HIV Infection Irrelevant to the drug concentrations in patients (compare with genotype GG); Irrelevant to the increased drug discontinuation in patients (compare with genotype GG) [195], [196]
Paclitaxel Drug Info Breast Neoplasm Irrelevant to the increased drug response in patients (compare with genotype GG) [197]
Atazanavir Drug Info HIV Infection Irrelevant to the increased drug discontinuation in patients (compare with genotype GG) [195]
Efavirenz Drug Info HIV Infection Irrelevant to the increased drug minimum plasma or PBMC concentrations in patients (compare with genotype GG) [198]
Omeprazole Drug Info Gastroesophageal Reflux Correlated with the increased drug concentrations in patients (compare with genotype GG) [199]
Genotypes AG + GG
Tacrolimus Drug Info Liver Transplantation Correlated with the increased drug clearance in patients (compare with genotype AA) [195]
Tacrolimus Drug Info Kidney Transplantation Correlated with the increased drug clearance in patients (compare with genotype AA); Correlated with the increased drug dose-adjusted trough concentrations in patients (compare with genotype AA); Irrelevant to the drug metabolism in patients (compare with genotype AA) [81], [197], [198]
Lamivudine Drug Info HIV Infection Correlated with the increased drug resistance in patients (compare with genotype AA) [199]
Lopinavir Drug Info HIV Infection Correlated with the increased drug resistance in patients (compare with genotype AA) [199]
Zidovudine Drug Info HIV Infection Correlated with the increased drug resistance in patients (compare with genotype AA) [199]
Ritonavir Drug Info HIV Infection Correlated with the increased drug resistance in patients (compare with genotype AA) [199]
Gemcitabine Drug Info Neoplasm Irrelevant to the decreased clinical outcome in patients (compare with genotype AA) [200]
Epirubicin Drug Info Neoplasm Irrelevant to the decreased clinical outcome in patients (compare with genotype AA) [200]
Docetaxel Drug Info Neoplasm Irrelevant to the decreased clinical outcome in patients (compare with genotype AA) [200]
Cisplatin Drug Info Neoplasm Irrelevant to the decreased clinical outcome in patients (compare with genotype AA) [200]
Tacrolimus Drug Info Ulcerative Colitis Irrelevant to the drug metabolism in patients (compare with genotype AA); Irrelevant to the drug response in patients (compare with genotype AA) [201]
Fluorouracil Drug Info Colorectal Neoplasm Irrelevant to the prognosis in patients (compare with genotype AA) [131]
Leucovorin Drug Info Colorectal Neoplasm Irrelevant to the prognosis in patients (compare with genotype AA) [131]
Cisplatin Drug Info Colorectal Neoplasm Irrelevant to the prognosis in patients (compare with genotype AA) [131]
Capecitabine Drug Info Neoplasm Irrelevant to the decreased clinical outcome in patients (compare with genotype AA) [200]
Genetic Polymorphism rs1128503
Site of GPD chr7:87550285 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP A>G
Minor Allele Frequency A=0.4161/2084 (Global)
Allele A
Simvastatin Drug Info Hypercholesterolemia Correlated with the decreased myalgia risk in patients (compare with allele G) [3]
Digoxin Drug Info Congestive Cardiac Insufficiency; Arrhythmias; Heart Failure Correlated with the increased drug serum concentrations in patients (compare with allele G) [13]
Codeine Drug Info Pain Correlated with the increased likelihood of CnS depression when used drug (compare with allele G) [14]
Phenytoin Drug Info Healthy Individuals Correlated with the increased plasma drug levels in healthy individual (compare with genotype GG) [21]
Tacrolimus Drug Info Kidney Transplantation Irrelevant to the dose-adjusted trough concentrations in patients (compare with allele G); Irrelevant to the drug clearance in patients (compare with Allele G); Irrelevant to the drug metabolism in patients (compare with Allele G) [24], [25], [27]
Cyclosporine Drug Info Kidney Transplantation Irrelevant to the drug clearance in patients (compare with allele G) [23]
Tacrolimus Drug Info Liver Transplantation Irrelevant to the drug clearance in patients (compare with Allele G); Irrelevant to the drug metabolism in patients (compare with Allele G) [36], [210]
Carbamazepine Drug Info Epilepsy Irrelevant to the drug concentrations in patients (compare with allele G); Irrelevant to the drug response in patients (compare with Allele G) [56], [18]
Methotrexate Drug Info Rheumatoid Arthritis Irrelevant to the drug discontinuation in patients (compare with allele G) [6]
Sirolimus Drug Info Kidney Transplantation Irrelevant to the drug metabolism in patients (compare with Allele G) [24]
Imatinib Drug Info Bcr-Abl Positive Chronic Myelogenous Leukemia Irrelevant to the drug response in patients (compare with Allele G) [37]
Valproic acid Drug Info Epilepsy Irrelevant to the drug response in patients (compare with Allele G) [56]
Phenytoin Drug Info Epilepsy Irrelevant to the drug response in patients (compare with Allele G) [56]
Phenobarbital Drug Info Epilepsy Irrelevant to the drug response in patients (compare with Allele G) [56]
Sunitinib Drug Info Renal Cell Carcinoma Irrelevant to the drug toxicity in patients (compare with allele G) [41]
Antiepileptics N.A. Epilepsy Irrelevant to the drug resistance in patients (compare with allele G); Irrelevant to the drug response in patients (compare with Allele G); Irrelevant to the likelihood of drug resistance in patients (compare with Allele G) [15], [217], [218]
Allele G
Methotrexate Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele A) [204]
Vincristine Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele A) [204]
Cisplatin Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele A) [204]
Doxorubicin Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele A) [204]
Cyclophosphamide Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele A) [204]
Carbamazepine Drug Info Epilepsy Irrelevant to the drug metabolism in patients (compare with allele A) [16]
Doxorubicin Drug Info Breast Neoplasm Irrelevant to the drug response in patients (compare with allele A) [206]
Cyclophosphamide Drug Info Breast Neoplasm Irrelevant to the drug response in patients (compare with allele A) [206]
Antiepileptics N.A. Epilepsy Irrelevant to the drug response in patients (compare with allele A) [72], [207]
Genotype AA
Tacrolimus Drug Info Kidney Transplantation Correlated with the decreased drug clearance in patients (compare with genotypes AG + GG); Irrelevant to the drug clearance in patients (compare with genotypes AG + GG); Irrelevant to the drug concentrations in patients (compare with genotypes AG + GG) [82], [208], [209]
Fentanyl Drug Info Neoplasm Correlated with the decreased drug response in patients (compare with Genotype AG + GG ) [85]
Sunitinib Drug Info Renal Cell Carcinoma Correlated with the decreased neutropenia risk in patients (compare with genotypes AG + GG) [90]
Gefitinib Drug Info Non-Small-Cell Lung Carcinoma Correlated with the increased diarrhea and exanthema risk in patients (compare with genotypes AG + GG) [212]
Tramadol Drug Info Pain Correlated with the increased drug exposure (compare with genotype GG) [104]
Fentanyl Drug Info Postoperative Pain Correlated with the increased likelihood of respiratory insufficiency in patients (compare with Genotype AG + GG) [107]
Cyclosporine Drug Info Kidney Transplantation Correlated with the increased nephrotoxicity risk in patients (compare with genotypes AG + GG) [215]
Oxaliplatin Drug Info Colorectal Neoplasm Correlated with the increased overall survival in patients (compare with genotype GG) [131]
Simvastatin Drug Info Hypercholesterolemia Correlated with the increased reduction in total cholesterol in patients (compare with genotype GG) [109]
Sirolimus Drug Info Kidney Transplantation Correlated with the increased triglycerides in patients (compare with genotypes AG + GG) [187]
Cyclosporine Drug Info Myasthenia Gravis Correlated with the increased trough blood concentration in patients (compare with genotype GG) [219]
Daunorubicin Drug Info Acute Myeloid Leukemia Irrelevant to the drug response in patients (compare with genotypes AG + GG) [111]
Cytarabine Drug Info Acute Myeloid Leukemia Irrelevant to the drug response in patients (compare with genotypes AG + GG) [111]
Tacrolimus Drug Info Ulcerative Colitis Irrelevant to the increased success rate in achieving short-term remission in patients (compare with genotypes AG + GG) [221]
Rocuronium Drug Info Muscle Relaxant Correlated with the increased drug response in patients (compare with genotypes AG + GG) [222]
Dexrazoxane Drug Info Acute Myeloid Leukemia Irrelevant to the drug response in patients (compare with genotypes AG + GG) [111]
Efavirenz Drug Info HIV Infection Correlated with the decreased drug concentrations in patients (compare with genotypes AG + GG) [115]
Capecitabine Drug Info Colorectal Neoplasm Correlated with the decreased hand-foot syndrome and neutropenia risk in patients (compare with genotype GG) [136]
Tipifarnib N.A. Neoplasm Correlated with the decreased drug metabolism in patients (compare with genotypes AG + GG) [225]
Platinum compounds N.A. Non-Small-Cell Lung Carcinoma Correlated with the increased drug toxicity risk in patients (compare with genotype GG); Correlated with the increased drug toxicity risk in patients (compare with genotypes AG + GG) [226]
Genotype AG
Tacrolimus Drug Info Kidney Transplantation Correlated with the increased drug trough concentrations in patients (compare with genotype GG) [216]
Methotrexate Drug Info Rheumatoid Arthritis; Precursor Cell Lymphoblastic Leukemia-Lymphoma Correlated with the increased likelihood of drug toxicity in patients (compare with genotype GG) [217]
Oxaliplatin Drug Info Colorectal Neoplasm Correlated with the increased overall survival in patients (compare with genotype GG) [131]
Modafinil Drug Info Narcolepsy Correlated with the increased drug response in patients (compare with genotypes AA + GG) [133]
Genotype GG
Tacrolimus Drug Info Liver Transplantation Correlated with the decreased drug concentrations in patients (compare with genotypes AA + AG) [218]
Sirolimus Drug Info Urinary Bladder Neoplasm Correlated with the decreased drug exposure in patients (compare with genotypes AA + AG) [219]
Temsirolimus Drug Info Urinary Bladder Neoplasm Correlated with the decreased drug exposure in patients (compare with genotypes AA + AG) [219]
Simvastatin Drug Info Hypercholesterolemia Correlated with the decreased drug response in patients (compare with genotypes AA + AG) [3]
Imatinib Drug Info Bcr-Abl Positive Chronic Myelogenous Leukemia Correlated with the decreased drug response in patients (compare with genotypes AA + AG); Correlated with the increased drug response in patients (compare with genotypes AA + AG) [106], [155]
Cytarabine Drug Info Acute Myeloid Leukemia Correlated with the decreased survival in patients (compare with genotypes AA + AG) [160]
Gefitinib Drug Info Non-Small-Cell Lung Carcinoma Irrelevant to the drug toxicity risk in patients (compare with genotypes AA + AG) [224]
Sevoflurane Drug Info Tonsillectomy Correlated with the decreased likelihood of adverse events in patients (compare with genotypes AA + AG); Correlated with the increased drug response in patients (compare with genotypes AA + AG) [225]
Remifentanil Drug Info Tonsillectomy Correlated with the increased drug response (compare with genotypes AA + AG); Correlated with the increased drug response in patients (compare with genotypes AA + AG) [225], [226]
Propofol Drug Info Anesthesia Correlated with the increased drug response (compare with genotypes AA + AG) [226]
Genotypes AA + AG
Sunitinib Drug Info Renal Cell Carcinoma Correlated with the decreased diarrhea risk in patients (compare with genotype GG) [90]
Carbamazepine Drug Info Epilepsy Correlated with the increased drug clearance in patients (compare with genotype GG) [224]
Clopidogrel Drug Info Acute Coronary Syndrome Correlated with the increased drug resistance (compare with genotype GG) [152]
Risperidone Drug Info Autistic Disorder Correlated with the increased drug response in patients (compare with genotype GG) [226]
Methotrexate Drug Info Precursor Cell Lymphoblastic Leukemia-Lymphoma Correlated with the increased drug toxicity risk in patients (compare with genotype GG) [185]
Tacrolimus Drug Info Heart Transplantation Correlated with the increased infection risk in patients (compare with genotype GG) [228]
Cyclosporine Drug Info Heart Transplantation Correlated with the increased infection risk in patients (compare with genotype GG) [228]
Cytarabine Drug Info Acute Multiple Myeloma Correlated with the increased overall survival in patients (compare with genotype GG) [189]
Genotypes AG + GG
Tacrolimus Drug Info Ulcerative Colitis Correlated with the increased drug response in patients (compare with genotype AA); Irrelevant to the drug metabolism in patients (compare with genotype AA) [200]
Methotrexate Drug Info Precursor Cell Lymphoblastic Leukemia-Lymphoma Irrelevant to the mucositis risk in patients (compare with genotype AA) [38]
Genetic Polymorphism rs2032582
Site of GPD chr7:87531302 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP A>C / A>T
Minor Allele Frequency A=0.3343/1674 (Global)
Allele A
Digoxin Drug Info Congestive Cardiac Insufficiency; Arrhythmias; Heart Failure Correlated with the increased drug serum concentrations in patients (compare with allele C) [13]
Everolimus Drug Info Breast Neoplasm Correlated with the increased likelihood of lymphopenia in patients (compare with allele C) [19]
Mycophenolate mofetil Drug Info Kidney Transplantation Correlated with the increased transplant rejection risk in patients (compare with genotype CC) [228]
Cyclosporine Drug Info Kidney Transplantation Correlated with the increased transplant rejection risk in patients (compare with genotype CC) [228]
Atorvastatin Drug Info Hypercholesterolemia Irrelevant to the dose decrease or drug switching risk in patients (compare with Allele T) [58]
Simvastatin Drug Info Hypercholesterolemia Irrelevant to the dose decrease or drug switching risk in patients (compare with Allele T) [58]
Tacrolimus Drug Info Kidney Transplantation Irrelevant to the dose-adjusted trough concentrations in patients (compare with allele C); Irrelevant to the drug trough concentrations in patients (compare with Allele C) [26], [31]
Tacrolimus Drug Info Hemopoietic Stem Cell Transplant Irrelevant to the drug clearance in patients (compare with Allele C) [35]
Tacrolimus Drug Info Liver Transplantation Irrelevant to the drug metabolism in patients (compare with Allele C) [201]
Clomipramine Drug Info Depression Correlated with the increased suicidal ideation risk in patients (compare with allele C) [234]
Nefazodone Drug Info Depression Correlated with the increased suicidal ideation risk in patients (compare with allele C) [234]
Fluoxetine Drug Info Depressive Disorder Correlated with the increased drug response in patients (compare with allele C) [235]
Venlafaxine Drug Info Depression Correlated with the increased suicidal ideation risk in patients (compare with allele C) [234]
Efavirenz Drug Info HIV Infection Correlated with the decreased likelihood of emerging viral drug resistance in patients (compare with allele C) [4]
Paroxetine Drug Info Depression Correlated with the increased suicidal ideation risk in patients (compare with allele C) [234]
Lithium N.A. Depression Correlated with the increased suicidal ideation risk in patients (compare with allele C) [234]
Antiepileptics N.A. Epilepsy Irrelevant to the likelihood of drug resistance in patients (compare with Allele C) [203]
Allele C
Atorvastatin Drug Info Coronary Artery Disease Correlated with the increased drug-induced liver injury risk in patients (compare with Allele T) [229]
Sirolimus Drug Info Kidney Transplantation Irrelevant to the drug metabolism in patients (compare with Allele A) [24]
Tacrolimus Drug Info Kidney Transplantation Irrelevant to the drug metabolism in patients (compare with Allele A) [24]
Carbamazepine Drug Info Epilepsy Irrelevant to the drug metabolism in patients (compare with Allele A); Irrelevant to the increased drug response in patients (compare with Allele T) [15], [16]
Pravastatin Drug Info Hyperlipoproteinemia Irrelevant to the drug response in patients (compare with allele A) [233]
Valproic acid Drug Info Epilepsy Irrelevant to the increased drug response in patients (compare with Allele T) [15]
Phenytoin Drug Info Epilepsy Irrelevant to the increased drug response in patients (compare with Allele T) [15]
Phenobarbital Drug Info Epilepsy Irrelevant to the increased drug response in patients (compare with Allele T) [15]
Fluoxetine Drug Info Depressive Disorder Irrelevant to the increased fluoxetine/in patients (S)-norfluoxetine ratio in patients (compare with Allele A) [228]
Antiepileptics N.A. Epilepsy Irrelevant to the drug response in patients (compare with Allele A) [72], [206]
Allele T
Carbamazepine Drug Info Epilepsy Correlated with the drug-resistant phenotype in patients (compare with allele C) [202]
Valproic acid Drug Info Epilepsy Correlated with the drug-resistant phenotype in patients (compare with allele C) [202]
Phenytoin Drug Info Epilepsy Correlated with the drug-resistant phenotype in patients (compare with allele C) [202]
Atorvastatin Drug Info Hypercholesterolemia Correlated with the increased drug response in patients (compare with allele A); Correlated with the increased drug response in patients(compare with allele C) [232]
Clopidogrel Drug Info Coronary Artery Disease Correlated with the increased Hemorrhage risk in patients (compare with allele A) [233]
Genotype AA
Doxorubicin Drug Info Breast Neoplasm Correlated with the decreased drug metabolism in patients (compare with genotype CC) [233]
Doxorubicin Drug Info Leukemia Correlated with the decreased drug metabolism in patients (compare with genotype CC) [233]
Anastrozole Drug Info Breast Neoplasm Correlated with the increased drug concentrations in patients (compare with genotypes AC + CC) [87]
Tramadol Drug Info Pain Correlated with the increased drug exposure (compare with genotype CC) [104]
Cyclosporine Drug Info Ulcerative Colitis Correlated with the increased drug resistance risk in patients (compare with genotypes CC + AC) [236]
Cyclosporine Drug Info Myasthenia Gravis Correlated with the increased drug trough blood concentration in patients (compare with genotype CC) [211]
Carbamazepine Drug Info Epilepsy Correlated with the increased likelihood of drug resistance in patients (compare with genotype CC) [16]
Fentanyl Drug Info Postoperative Pain Correlated with the increased likelihood of respiratory insufficiency in patients (compare with Genotype AA) [107]
Simvastatin Drug Info Hypercholesterolemia Correlated with the increased reduction in total cholesterol in patients (compare with genotype CC) [109]
Mitoxantrone Drug Info Breast Neoplasm Correlated with the increased sensitivity to drug in vitro (compare with genotypes CC + AC) [160]
Daunorubicin Drug Info Acute Myeloid Leukemia Irrelevant to the drug response in patients (compare with genotypes AC + CC) [111]
Cytarabine Drug Info Acute Myeloid Leukemia Irrelevant to the drug response in patients (compare with genotypes AC + CC) [111]
Nevirapine Drug Info HIV Infection Irrelevant to the drug metabolism in patients (compare with genotype CC) [170]
Dexrazoxane Drug Info Acute Myeloid Leukemia Irrelevant to the drug response in patients (compare with genotypes AC + CC) [111]
Efavirenz Drug Info HIV Infection Correlated with the decreased drug concentrations in patients (compare with genotypes AC + CC); Irrelevant to the drug metabolism in patients (compare with genotype CC) [115], [170]
Idarubicin Drug Info Acute Myeloid Leukemia Irrelevant to the drug response in patients (compare with genotypes AC + CC) [111]
Antiepileptics N.A. Epilepsy Correlated with the increased likelihood of drug resistance in patients (compare with genotype CC) [16]
Genotype AC
Methadone Drug Info Opioid-Related Disorders Correlated with the increased drug concentrations in patients (compare with genotypes AA + CC) [129]
Simvastatin Drug Info Hypercholesterolemia Correlated with the increased reduction in total cholesterol in patients (compare with genotype CC) [109]
Genotype AT
Tacrolimus Drug Info Kidney Transplantation Irrelevant to the drug clearance in patients (compare with allele C) [23]
Cyclosporine Drug Info Kidney Transplantation Irrelevant to the drug clearance in patients (compare with allele C) [23]
Genotype CC
Methadone Drug Info Opioid-Related Disorders Correlated with the decreased drug clearance in patients (compare with genotypes AC + Ct) [235]
Rivaroxaban Drug Info Healthy Individuals Correlated with the decreased drug exposure in healthy individuals (compare with genotypes AA + AC) [183]
Dabigatran Drug Info Healthy Individuals Correlated with the decreased drug exposure in healthy individuals (compare with genotypes AA + AC) [183]
Verapamil Drug Info Healthy Individuals Correlated with the decreased drug metabolism in healthy individuals (compare with genotypes AA + AC) [140]
Cytarabine Drug Info Acute Multiple Myeloma Correlated with the decreased survival in patients (compare with genotypes AA + AC) [160]
Cyclosporine Drug Info Cystic Fibrosis Correlated with the increased drug clearance in patients (compare with genotype AA) [144]
Dicloxacillin Drug Info Cystic Fibrosis Correlated with the increased drug clearance in patients (compare with genotype AA) [144]
Digoxin Drug Info Congestive Cardiac Insufficiency; Arrhythmias; Heart Failure Correlated with the increased drug metabolism (compare with genotype AA) [147]
Temsirolimus Drug Info Urinary Bladder Neoplasm Correlated with the increased drug metabolism in patients (compare with genotypes AA + AC) [219]
Atorvastatin Drug Info Hypercholesterolemia Correlated with the increased drug response in patients (compare with genotype AA) [141]
Pravastatin Drug Info Acute Coronary Syndrome Correlated with the increased percent reduction in LDL-cholesterol in patients [243]
Capecitabine Drug Info Colorectal Neoplasm Correlated with the increased hand-foot syndrome risk in patients (compare with genotype AA) [136]
Anthracyclines N.A. Breast Neoplasm Correlated with the increased drug resistance risk in patients (compare with genotype AC) [126]
Genotypes AA + AC
Atorvastatin Drug Info Hypercholesterolemia Correlated with the increased drug response in patients (compare with genotype CC) [237]
Cytarabine Drug Info Acute Myeloid Leukemia Irrelevant to the increased overall survival in patients (compare with genotype CC) [189]
Genotypes AA + AT
Sunitinib Drug Info Renal Cell Carcinoma Correlated with the decreased overall survival in patients (compare with genotypes AC + CC) [238]
Paclitaxel Drug Info Ovarian Neoplasm Correlated with the increased drug response in patients (compare with genotypes AC + CC) [239]
Genotypes AA + TT
Tacrolimus Drug Info Nephrotic Syndrome Correlated with the increased drug response in patients (compare with genotypes CC + CT) [240]
Genotypes AC + CC
Cyclosporine Drug Info Kidney Transplantation Correlated with the decreased drug dose-adjusted trough concentrations as in patients (compare with genotypes AA + Ct); Correlated with the increased drug dose in patients (compare with genotypes AA + Ct) [241]
Ritonavir Drug Info HIV Infection Correlated with the drug concentrations in patients (compare with genotype AA) [242]
Tacrolimus Drug Info Kidney Transplantation Correlated with the increased drug dose-adjusted trough concentrations in patients (compare with genotype AA) [81]
Fentanyl Drug Info Neoplasm Correlated with the increased likelihood of constipation in patients (compare with genotype AA) [85]
Genotypes AC + CT
Tacrolimus Drug Info Kidney Transplantation Correlated with the increased drug trough concentrations in patients (compare with genotype CC) [216]
Modafinil Drug Info Narcolepsy Correlated with the increased drug response in patients (compare with genotype CC) [133]
Genotypes CC + CT
Fentanyl Drug Info Neoplasm Correlated with the increased likelihood of constipation in patients (compare with Genotype TT) [85]
Tacrolimus Drug Info Kidney Transplantation Irrelevant to the drug metabolism in patients (compare with genotypes AC + At) [60]
Genotypes CT + TT
Doxorubicin Drug Info Breast Neoplasm Correlated with the decreased survival in patients(compare with Genotypes AC + CC) [243]
Cyclophosphamide Drug Info Breast Neoplasm Correlated with the decreased survival in patients(compare with Genotypes AC + CC) [243]
Genotypes AT + CT
Efavirenz Drug Info HIV Infection Irrelevant to the increased drug plasma exposure in patients (compare with genotypes CC + CT) [4]
Genetic Polymorphism rs11983225
Site of GPD chr7:87532204 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP T>C
Minor Allele Frequency C=0.1456/729 (Global)
Allele C
Citalopram Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele T) [244]
Amitriptyline Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele T) [244]
Venlafaxine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele T) [244]
Paroxetine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele T) [244]
Genetic Polymorphism rs12720067
Site of GPD chr7:87540040 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP C>T
Minor Allele Frequency T=0.0899/450 (Global)
Allele T
Citalopram Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Amitriptyline Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Venlafaxine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Paroxetine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Genetic Polymorphism rs17160359
Site of GPD chr7:87717503 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP G>A / G>T
Minor Allele Frequency T=0.0092/46 (Global)
Allele T
Fluorouracil Drug Info Neoplasm Correlated with the increased drug response in patients (compare with allele G) [245]
Capecitabine Drug Info Neoplasm Correlated with the increased drug response in patients (compare with allele G) [245]
Genetic Polymorphism rs1922242
Site of GPD chr7:87544351 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP A>T
Minor Allele Frequency T=0.3790/1898 (Global)
Genotype AA
Fluvastatin Drug Info Hypercholesterolemia Correlated with the increased drug response in patients (compare with genotype At) [246]
Genetic Polymorphism rs2032583
Site of GPD chr7:87531245 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP A>G
Minor Allele Frequency G=0.1454/728 (Global)
Allele G
Citalopram Drug Info Major Depressive Disorder Correlated with the increased likelihood of adverse effects in patients (compare with Allele A) [247]
Fluvoxamine Drug Info Major Depressive Disorder Correlated with the increased likelihood of adverse effects in patients (compare with Allele A) [247]
Venlafaxine Drug Info Major Depressive Disorder Correlated with the increased likelihood of adverse effects in patients (compare with Allele A) [247]
Sertraline Drug Info Major Depressive Disorder Correlated with the increased likelihood of adverse effects in patients (compare with Allele A) [247]
Paroxetine Drug Info Major Depressive Disorder Correlated with the increased likelihood of adverse effects in patients (compare with Allele A) [247]
Genotype GG
Citalopram Drug Info Bipolar Disorder Irrelevant to the drug response in patients (compare with genotypes AA + AG) [248]
Amitriptyline Drug Info Bipolar Disorder Irrelevant to the drug response in patients (compare with genotypes AA + AG) [248]
Venlafaxine Drug Info Bipolar Disorder Irrelevant to the drug response in patients (compare with genotypes AA + AG) [248]
Sertraline Drug Info Bipolar Disorder Irrelevant to the drug response in patients (compare with genotypes AA + AG) [248]
Escitalopram Drug Info Bipolar Disorder Irrelevant to the drug response in patients (compare with genotypes AA + AG) [248]
Paroxetine Drug Info Bipolar Disorder Irrelevant to the drug response in patients (compare with genotypes AA + AG) [248]
Nortriptyline Drug Info Bipolar Disorder Irrelevant to the drug response in patients (compare with genotypes AA + AG) [248]
Trimipramine Drug Info Bipolar Disorder Irrelevant to the drug response in patients (compare with genotypes AA + AG) [248]
Selective serotonin reuptake inhibitors N.A. Bipolar Disorder Irrelevant to the drug response in patients (compare with genotypes AA + AG) [248]
Genotypes AG + GG
Citalopram Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with genotype AA) [244]
Fluvoxamine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with genotype AA) [244]
Amitriptyline Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with genotype AA) [244]
Venlafaxine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with genotype AA) [244]
Sertraline Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with genotype AA) [244]
Paroxetine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with genotype AA) [244]
Antidepressants N.A. Depression Correlated with the increased likelihood of remission in patients (compare with genotype AA) [244]
Genetic Polymorphism rs2229109
Site of GPD chr7:87550493 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP C>A / C>T
Minor Allele Frequency T=0.0126/63 (Global)
Allele C
Dexamethasone Drug Info Multiple Myeloma Irrelevant to the anemia, neutropenia or thrombocytopenia risk in patients (compare with Allele T) [249]
Lenalidomide Drug Info Multiple Myeloma Irrelevant to the anemia, neutropenia or thrombocytopenia risk in patients (compare with Allele T) [249]
Genotype CT
Vincristine Drug Info Non-Hodgkin Lymphoma Correlated with the increased diarrhea and vomiting risk in patients (compare with genotype CC) [250]
Doxorubicin Drug Info Non-Hodgkin Lymphoma Correlated with the increased diarrhea and vomiting risk in patients (compare with genotype CC) [250]
Cyclophosphamide Drug Info Non-Hodgkin Lymphoma Correlated with the increased diarrhea and vomiting risk in patients (compare with genotype CC) [250]
Methotrexate Drug Info Precursor Cell Lymphoblastic Leukemia-Lymphoma Correlated with the increased drug resistance in patients (compare with genotype CC) [93]
Vincristine Drug Info Precursor Cell Lymphoblastic Leukemia-Lymphoma Correlated with the increased drug resistance in patients (compare with genotype CC) [93]
Doxorubicin Drug Info Precursor Cell Lymphoblastic Leukemia-Lymphoma Correlated with the increased drug resistance in patients (compare with genotype CC) [93]
Prednisolone Drug Info Precursor Cell Lymphoblastic Leukemia-Lymphoma Correlated with the increased drug resistance in patients (compare with genotype CC) [93]
Dexamethasone Drug Info Multiple Myeloma Correlated with the increased likelihood of progression-free survival in patients (compare with genotype CC); Irrelevant to the likelihood of overall survival in patients (compare with genotype CC) [249]
Lenalidomide Drug Info Multiple Myeloma Correlated with the increased likelihood of progression-free survival in patients (compare with genotype CC); Irrelevant to the likelihood of overall survival in patients (compare with genotype CC) [249]
Valganciclovir Drug Info Kidney Transplantation Correlated with the increased neutropenia risk in patients (compare with genotype CC) [253]
Prednisone Drug Info Non-Hodgkin Lymphoma Correlated with the increased diarrhea and vomiting risk in patients (compare with genotype CC) [250]
Rituximab Drug Info Non-Hodgkin Lymphoma Correlated with the increased diarrhea and vomiting risk in patients (compare with genotype CC) [250]
Bleomycin Drug Info Non-Hodgkin Lymphoma Correlated with the increased diarrhea and vomiting risk in patients (compare with genotype CC) [250]
Vindesine Drug Info Non-Hodgkin Lymphoma Correlated with the increased diarrhea and vomiting risk in patients (compare with genotype CC) [250]
Genotypes CT + TT
Tacrolimus Drug Info Kidney Transplantation Correlated with the increased renal transplant failure risk in patients (compare with genotype CC) [180]
Genetic Polymorphism rs2235015
Site of GPD chr7:87570248 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP C>A / C>T
Minor Allele Frequency A=0.2157/1080 (Global)
Allele A
Citalopram Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Amitriptyline Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Venlafaxine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Paroxetine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Genotype AA
Citalopram Drug Info Depression Irrelevant to the drug response in patients (compare with genotypes AA + AC) [248]
Amitriptyline Drug Info Depression Irrelevant to the drug response in patients (compare with genotypes AA + AC) [248]
Venlafaxine Drug Info Depression Irrelevant to the drug response in patients (compare with genotypes AA + AC) [248]
Sertraline Drug Info Depression Irrelevant to the drug response in patients (compare with genotypes AA + AC) [248]
Escitalopram Drug Info Depression Irrelevant to the drug response in patients (compare with genotypes AA + AC) [248]
Paroxetine Drug Info Depression Irrelevant to the drug response in patients (compare with genotypes AA + AC) [248]
Nortriptyline Drug Info Depression Irrelevant to the drug response in patients (compare with genotypes AA + AC) [248]
Trimipramine Drug Info Depression Irrelevant to the drug response in patients (compare with genotypes AA + AC) [248]
Selective serotonin reuptake inhibitors N.A. Depression Irrelevant to the drug response in patients (compare with genotypes AA + AC) [248]
Genetic Polymorphism rs2235040
Site of GPD chr7:87536434 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP C>A / C>G / C>T
Minor Allele Frequency T=0.1396/699 (Global)
Allele T
Citalopram Drug Info Major Depressive Disorder Correlated with the increased likelihood of adverse effects in patients (compare with allele C) [247]
Fluvoxamine Drug Info Major Depressive Disorder Correlated with the increased likelihood of adverse effects in patients (compare with allele C) [247]
Citalopram Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Amitriptyline Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Venlafaxine Drug Info Major Depressive Disorder Correlated with the increased likelihood of adverse effects in patients (compare with allele C) [247]
Venlafaxine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Sertraline Drug Info Major Depressive Disorder Correlated with the increased likelihood of adverse effects in patients (compare with allele C) [247]
Paroxetine Drug Info Major Depressive Disorder Correlated with the increased likelihood of adverse effects in patients (compare with allele C) [247]
Paroxetine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Genotype CT
Imatinib Drug Info Gastrointestinal Stromal Tumors Correlated with the decreased periorbital edema risk in patients (compare with genotype CC) [252]
Genetic Polymorphism rs2235047
Site of GPD chr7:87509216 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP A>C / A>G
Minor Allele Frequency C=0.1745/874 (Global)
Allele C
Daunorubicin Drug Info Neoplasm Irrelevant to the likelihood of cardiotoxicity in patients (compare with Allele A) [253]
Doxorubicin Drug Info Neoplasm Irrelevant to the likelihood of cardiotoxicity in patients (compare with Allele A) [253]
Anthracyclines N.A. Neoplasm Correlated with the increased likelihood of cardiotoxicity in patients (compare with Allele A) [254]
Genetic Polymorphism rs2235067
Site of GPD chr7:87520606 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP C>T
Minor Allele Frequency T=0.1338/670 (Global)
Allele T
Citalopram Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Amitriptyline Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Venlafaxine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Paroxetine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Genetic Polymorphism rs28401781
Site of GPD chr7:87519012 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP C>T
Minor Allele Frequency T=0.1474/738 (Global)
Allele T
Citalopram Drug Info Major Depressive Disorder Correlated with the increased drug response in patients (compare with allele C) [255]
Fluoxetine Drug Info Major Depressive Disorder Correlated with the increased drug response in patients (compare with allele C) [255]
Sertraline Drug Info Major Depressive Disorder Correlated with the increased drug response in patients (compare with allele C) [255]
Paroxetine Drug Info Major Depressive Disorder Correlated with the increased drug response in patients (compare with allele C) [255]
Genetic Polymorphism rs3213619
Site of GPD chr7:87600877 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP A>G
Minor Allele Frequency G=0.0543/272 (Global)
Allele G
Atenolol Drug Info Hypertension Correlated with the increased hypercholesterolemia risk in patients (compare with Allele A) [256]
Genetic Polymorphism rs3789243
Site of GPD chr7:87591570 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP A>G
Minor Allele Frequency A=0.4635/2321 (Global)
Allele A
Antiepileptics N.A. Epilepsy Irrelevant to the likelihood of drug resistance in patients (compare with Allele G) [203]
Genetic Polymorphism rs4148737
Site of GPD chr7:87541836 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP T>C
Minor Allele Frequency C=0.3790/1898 (Global)
Allele C
Methotrexate Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele T) [204]
Vincristine Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele T) [204]
Cisplatin Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele T) [204]
Doxorubicin Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele T) [204]
Cyclophosphamide Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele T) [204]
Doxorubicin Drug Info Breast Neoplasm Irrelevant to the drug response in patients (compare with Allele T) [205]
Cyclophosphamide Drug Info Breast Neoplasm Irrelevant to the drug response in patients (compare with Allele T) [205]
Genetic Polymorphism rs4148739
Site of GPD chr7:87531733 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP T>C
Minor Allele Frequency C=0.1454/728 (Global)
Allele C
Citalopram Drug Info Major Depressive Disorder Correlated with the increased drug response in patients (compare with Allele T) [255]
Citalopram Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele T) [244]
Amitriptyline Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele T) [244]
Fluoxetine Drug Info Major Depressive Disorder Correlated with the increased drug response in patients (compare with Allele T) [255]
Fluoxetine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele T) [244]
Venlafaxine Drug Info Major Depressive Disorder Correlated with the increased drug response in patients (compare with Allele T) [255]
Venlafaxine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele T) [244]
Sertraline Drug Info Major Depressive Disorder Correlated with the increased drug response in patients (compare with Allele T) [255]
Sertraline Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele T) [244]
Paroxetine Drug Info Major Depressive Disorder Correlated with the increased drug response in patients (compare with Allele T) [255]
Paroxetine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele T) [244]
Genotype TT
Carbamazepine Drug Info Epilepsy Correlated with the decreased drug metabolism in patients (compare with genotype Ct) [223]
Genetic Polymorphism rs4148740
Site of GPD chr7:87522787 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP A>G
Minor Allele Frequency G=0.1446/724 (Global)
Allele G
Citalopram Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele A) [244]
Amitriptyline Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele A) [244]
Venlafaxine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele A) [244]
Paroxetine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele A) [244]
Genotype AG
Carbamazepine Drug Info Epilepsy Correlated with the increased drug metabolism in patients (compare with genotype AA) [223]
Genetic Polymorphism rs4728709
Site of GPD chr7:87604286 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP G>A
Minor Allele Frequency A=0.1769/886 (Global)
Allele A
Vincristine Drug Info Precursor Cell Lymphoblastic Leukemia-Lymphoma Correlated with the decreased neurotoxicity syndromes risk in patients (compare with allele G) [2]
Genetic Polymorphism rs7787082
Site of GPD chr7:87527735 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP G>A
Minor Allele Frequency A=0.3778/1892 (Global)
Allele A
Citalopram Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Amitriptyline Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Venlafaxine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Paroxetine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with allele C) [244]
Allele G
Clozapine Drug Info Schizophrenia Correlated with the decreased drug response in patients (compare with Allele A) [257]
Genetic Polymorphism rs9282564
Site of GPD chr7:87600124 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP T>A / T>C / T>G
Minor Allele Frequency C=0.0260/130 (Global)
Allele C
Methadone Drug Info Opioid-Related Disorders Correlated with the decreased drug clearance in patients (compare with Allele T) [1]
Allele T
Tacrolimus Drug Info Kidney Transplantation Irrelevant to the drug trough concentration in patients (compare with allele C) [258]
Genotype CT
Tacrolimus Drug Info Lung Transplantation Correlated with the increased drug concentrations in patients (compare with Genotype TT) [182]
Genotypes CC + CT
Tacrolimus Drug Info Kidney Transplantation Correlated with the decreased drug dose-adjusted trough concentrations in patients (compare with Genotype TT) [259]
Morphine Drug Info Neoplasm Correlated with the increased respiratory insufficiency risk (compare with Genotype TT) [260]
Genetic Polymorphism rs10248420
Site of GPD chr7:87535670 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP A>G / A>T
Minor Allele Frequency G=0.3474/1740 (Global)
Allele A
Clozapine Drug Info Schizophrenia Correlated with the decreased drug response in patients (compare with allele G) [257]
Allele G
Citalopram Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele A) [244]
Amitriptyline Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele A) [244]
Venlafaxine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele A) [244]
Paroxetine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele A) [244]
Genetic Polymorphism rs10267099
Site of GPD chr7:87649444 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP G>A
Minor Allele Frequency G=0.1434/718 (Global)
Allele G
Atenolol Drug Info Hypertension Correlated with the increased hypercholesterolemia risk in patients (compare with Allele A) [256]
Genetic Polymorphism rs10276036
Site of GPD chr7:87550882 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP C>A / C>T
Minor Allele Frequency C=0.4323/2165 (Global)
Allele A
Doxorubicin Drug Info Breast Neoplasm Irrelevant to the drug response in patients (compare with Allele T) [205]
Cyclophosphamide Drug Info Breast Neoplasm Irrelevant to the drug response in patients (compare with Allele T) [205]
Allele C
Methotrexate Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele T) [204]
Vincristine Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele T) [204]
Cisplatin Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele T) [204]
Doxorubicin Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele T) [204]
Cyclophosphamide Drug Info Osteosarcoma Correlated with the increased death risk in patients (compare with Allele T) [204]
Genetic Polymorphism rs10280101
Site of GPD chr7:87524269 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP A>C / A>G
Minor Allele Frequency C=0.1446/724 (Global)
Allele C
Citalopram Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele A) [244]
Amitriptyline Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele A) [244]
Venlafaxine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele A) [244]
Paroxetine Drug Info Depression Correlated with the increased likelihood of remission in patients (compare with Allele A) [244]
Genetic Polymorphism rs3842
Site of GPD chr7:87504050 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP T>C
Minor Allele Frequency C=0.1879/941 (Global)
Allele C
Efavirenz Drug Info HIV Infection Correlated with the drug concentrations in patients (compare with Allele T); Correlated with the drug metabolism in patients (compare with Allele T); Irrelevant to the drug concentrations in patients (compare with Allele T) [261], [262], [263]
Genotypes CC + CT
Efavirenz Drug Info HIV Infection Correlated with the increased drug accumulation in patients (compare with Genotype TT); Correlated with the increased drug trough concentration in patients (compare with Genotype TT) [193], [265]
Genetic Polymorphism rs12720066
Site of GPD chr7:87540386 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP A>C
Minor Allele Frequency C=0.0212/106 (Global)
Genotypes AC + CC
Irinotecan Drug Info Colorectal Neoplasm Correlated with the increased severity of neutropenia in patients (compare with genotype AA) [265]
Genetic Polymorphism rs4148738
Site of GPD chr7:87533733 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP C>T
Minor Allele Frequency C=0.3814/1910 (Global)
Genotypes CT + TT
Dabigatran Drug Info Atrial Fibrillation Correlated with the decreased drug concentrations in patients (compare with genotype CC) [266]
References
1 ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006 Dec;80(6):668-81.
2 Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014 Jun;15(8):1105-16.
3 The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther. 2005 Nov;78(5):551-8.
4 Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005 Dec 1;192(11):1931-42.
5 Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis. 2006 Sep 15;43(6):779-82.
6 Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Pharmacogenomics J. 2017 Oct;17(5):412-418.
7 Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Sci Rep. 2018 May 9;8(1):7342.
8 Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics. 2010 Feb;11(2):163-75.
9 Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease. Eur J Clin Pharmacol. 2017 Jul;73(7):843-854.
10 Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther. 2012 Feb;91(2):257-63.
11 Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite. Eur J Clin Pharmacol. 2017 Dec;73(12):1623-1632.
12 Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol. 2013 May;69(5):1103-12.
13 Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics. 2008 Apr;18(4):299-305.
14 Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther. 2012 Apr;91(4):692-9.
15 Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. Biochimie. 2010 Sep;92(9):1207-12.
16 ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics. 2006 Jun;7(4):551-61.
17 Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese. Pharmacogenomics. 2009 May;10(5):723-32.
18 Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Epilepsy Res. 2015 Nov;117:52-7.
19 Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. PLoS One. 2017 Jul 20;12(7):e0180192.
20 The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J Clin Lipidol. 2011 Mar-Apr;5(2):91-6.
21 CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86.
22 The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther Drug Monit. 2006 Oct;28(5):668-72.
23 Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics. 2011 Sep;12(9):1293-303.
24 CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients. Springerplus. 2015 Oct 23;4:637.
25 Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit. 2012 Dec;34(6):680-5.
26 Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients. Genet Test Mol Biomarkers. 2017 Nov;21(11):663-673.
27 Pharmacogenotyping of CYP3A5 in predicting dose-adjusted trough levels of tacrolimus among Malaysian kidney-transplant patients. Can J Physiol Pharmacol. 2014 Jan;92(1):50-7.
28 CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics. 2014 Feb;15(2):179-88.
29 Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients. Int J Urol. 2016 Jun;23(6):484-90.
30 Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. Eur J Clin Pharmacol. 2013 Sep;69(9):1659-65.
31 MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol. 2004 Nov;58(5):548-53.
32 The impact of genetic polymorphisms on time required to attain the target tacrolimus levels and subsequent pharmacodynamic outcomes in pediatric kidney transplant patients. Saudi J Kidney Dis Transpl. 2014 Mar;25(2):266-77.
33 Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. Clin Pharmacokinet. 2015 Dec;54(12):1259-72.
34 Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. J Clin Psychopharmacol. 2013 Jun;33(3):289-98.
35 Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. Bone Marrow Transplant. 2011 Jan;46(1):90-7.
36 Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene. 2013 Jan 10;512(2):226-31.
37 Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia. Cancer Chemother Pharmacol. 2017 Oct;80(4):829-839.
38 Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget. 2017 Jun 6;8(23):37761-37772.
39 Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics. 2011 Sep;12(9):1269-80.
40 The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study. Basic Clin Pharmacol Toxicol. 2017 Jul;121(1):29-36.
41 Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer Chemother Pharmacol. 2013 Oct;72(4):825-35.
42 Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. Int J Cardiol. 2013 Sep 10;167(6):2882-8.
43 Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol. 2012 May 29;59(22):1928-37.
44 Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Thromb Haemost. 2013 Apr;109(4):744-54.
45 Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv. 2013 Nov;6(11):1166-75.
46 Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. JACC Cardiovasc Interv. 2010 Jul;3(7):731-41.
47 Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction. Circ Cardiovasc Genet. 2014 Jun;7(3):277-86.
48 The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. Pharmacogenet Genomics. 2014 Apr;24(4):204-10.
49 Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study. J Microbiol Immunol Infect. 2017 Dec;50(6):789-797.
50 Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. Laryngoscope. 2009 Aug;119(8):1484-90.
51 Effects of ABCB1, ABCC2, UGT2B7 and HNF4 genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy. Seizure. 2017 Oct;51:102-106.
52 Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics. 2010 Jan;11(1):23-31.
53 Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006 Sep 15;43(6):783-6.
54 Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. PLoS One. 2017 Oct 16;12(10):e0186200.
55 Lack of association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain. J Clin Pharmacol. 2012 Feb;52(2):234-42.
56 No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. Epilepsy Behav. 2009 Jan;14(1):78-82.
57 Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther Drug Monit. 2007 Jun;29(3):305-12.
58 Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf. 2010 Jan;19(1):75-81.
59 Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease. Eur J Clin Pharmacol. 2015 Sep;71(9):1091-7.
60 Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. Br J Clin Pharmacol. 2008 Aug;66(2):207-14.
61 Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis. Eur J Clin Pharmacol. 2015 Aug;71(8):959-65.
62 Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer. Pharmacogenomics. 2011 Feb;12(2):205-14.
63 Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. Thromb Res. 2012 Jul;130(1):70-4.
64 Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv. 2011 Dec 1;4(6):585-94.
65 Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis. 2006 Jan 15;42(2):291-5.
66 Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS. 2007 Jan 2;21(1):41-6.
67 Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics. 2007 Mar;8(3):227-35.
68 Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol. 2004 May;57(5):569-75.
69 Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. Cancer Epidemiol. 2010 Oct;34(5):634-8.
70 Chloride influx in human leucocytes: a triple-isotope technique for the assessment of chloride transporters. Clin Sci (Lond). 1991 Sep;81(3):405-12.
71 Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis. 2013 Jun 4;13:261.
72 Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. Pharmacogenomics. 2011 May;12(5):713-25.
73 Polymorphism of the multidrug resistance 1 gene MDR1/ABCB1 C3435T and response to antiepileptic drug treatment in temporal lobe epilepsy. Seizure. 2015 Jan;24:124-6.
74 Association of a polymorphism in MDR1 C3435T with response to antiepileptic drug treatment in ethic Han Chinese children with epilepsy. Zhongguo Dang Dai Er Ke Za Zhi. 2007 Feb;9(1):11-4.
75 Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia. 2005 May;46(5):643-7.
76 Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501.
77 ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One. 2012;7(10):e46366.
78 Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites. J Clin Pharm Ther. 2015 Apr;40(2):226-31.
79 C3435T polymorphism of the ABCB1 gene is associated with poor clopidogrel responsiveness in a Mexican population undergoing percutaneous coronary intervention. Thromb Res. 2015 Nov;136(5):894-8.
80 ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics. 2003 Nov;13(11):675-82.
81 The importance of MDR1 gene polymorphisms for tacrolimus dosage. Eur J Pharm Sci. 2016 Feb 15;83:109-13.
82 Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients. Br J Clin Pharmacol. 2014 Aug;78(2):364-72.
83 Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8.
84 Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001 Aug;70(2):189-99.
85 Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet. 2012;27(4):414-21.
86 Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis. Pharmacogenomics. 2017 Jan;18(2):175-195.
87 Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients. Br J Clin Pharmacol. 2017 Mar;83(3):562-571.
88 Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting. Anaesthesia. 2010 Oct;65(10):996-1000.
89 Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol. 2005 Jul;61(5-6):375-9.
90 Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. PLoS One. 2015 Aug 5;10(8):e0134102.
91 Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population. Pharmacogenomics J. 2017 Oct;17(5):471-478.
92 ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol. 2009 Aug;29(4):319-26.
93 Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015 Aug;15(4):372-9.
94 Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics. 2014 Aug;15(11):1479-94.
95 Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010 Oct 16;376(9749):1312-9.
96 Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011 Oct 26;306(16):1765-74.
97 Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 Jan 22;360(4):363-75.
98 A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics J. 2016 Feb;16(1):71-8.
99 Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002 Jan 5;359(9300):30-6.
100 ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis. Clin Chim Acta. 2015 May 20;445:79-84.
101 Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism. Xenobiotica. 2012 Dec;42(12):1248-54.
102 Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. Clin Pharmacokinet. 2016 Dec;55(12):1521-1533.
103 Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011 Nov;12(11):1525-33.
104 Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose. Forensic Sci Int. 2014 May;238:125-32.
105 ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. Pharmacogenomics. 2014 Jul;15(10):1297-309.
106 Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy? Leuk Lymphoma. 2017 Sep;58(9):1-9.
107 Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther. 2007 Apr;81(4):539-46.
108 Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008 Apr;83(4):559-66.
109 Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males. Pharmacogenomics. 2009 Nov;10(11):1743-51.
110 Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation. PLoS One. 2014 Oct 13;9(10):e109464.
111 Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia. Eur J Clin Pharmacol. 2015 Mar;71(3):293-302.
112 Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies. Pediatr Blood Cancer. 2016 Nov;63(11):1983-9.
113 CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009 Feb;49(2):196-204.
114 Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study. Pharmacogenomics J. 2017 Oct;17(5):435-440.
115 Efavirenz pharmacogenetics in a cohort of Italian patients. Int J Antimicrob Agents. 2016 Feb;47(2):117-23.
116 Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2003 Jan;73(1):20-30.
117 Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. J Antimicrob Chemother. 2015 Jan;70(1):307-8.
118 A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2002;2(3):191-6.
119 Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy. Support Care Cancer. 2018 May;26(5):1505-1513.
120 Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain. Asian Pac J Cancer Prev. 2013;14(5):2937-43.
121 Single-nucleotide polymorphism C3435T in the ABCB1 gene is associated with opioid consumption in postoperative pain. Pain Med. 2013 Dec;14(12):1977-84.
122 Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy. Epilepsy Res. 2014 Feb;108(2):251-6.
123 Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav. 2007 Aug;11(1):112-7.
124 Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One. 2011;6(12):e27810.
125 Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol. 2003 May;22(5):1117-21.
126 Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol. 2009 Feb;20(2):272-7.
127 Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis. OMICS. 2012 Nov;16(11):589-95.
128 Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Pharmgenomics Pers Med. 2013 Aug 26;6:93-8.
129 Relationship between ABCB1 polymorphisms and serum methadone concentration in patients undergoing methadone maintenance therapy (MMT). Am J Drug Alcohol Abuse. 2016 Sep;42(5):587-596.
130 Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. Am J Kidney Dis. 2018 Mar;71(3):315-326.
131 Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis. Pharmacogenomics. 2013 Jun;14(8):897-911.
132 Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients. PLoS One. 2015 Nov 10;10(11):e0142408.
133 Pharmacogenetics and Treatment Response in Narcolepsy Type 1: Relevance of the Polymorphisms of the Drug Transporter Gene ABCB1. Clin Neuropharmacol. 2016 Jan-Feb;39(1):18-23.
134 Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer. 2018 Aug;26(8):2911-2918.
135 Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics. 2008 Dec;18(12):1041-9.
136 ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics. 2010 Dec;11(12):1715-23.
137 Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010 Jul 10;28(20):3227-33.
138 The Effect of ABCB1 C3435T Polymorphism on Cyclosporine Dose Requirements in Kidney Transplant Recipients: A Meta-Analysis. Basic Clin Pharmacol Toxicol. 2015 Aug;117(2):117-25.
139 Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics. 2008 Apr;18(4):307-15.
140 Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. Br J Clin Pharmacol. 2009 Sep;68(3):395-401.
141 An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 2005;5(6):352-8.
142 MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics. 2008 May;18(5):383-9.
143 Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget. 2018 Jan 10;9(10):9114-9136.
144 Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. Pharmacotherapy. 2008 Jul;28(7):883-94.
145 Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics. 2014;15(15):1867-79.
146 Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):474-485.
147 Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 2002 Aug;72(2):209-19.
148 Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood. 2004 Jan 1;103(1):67-72.
149 Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. J Clin Pharm Ther. 2017 Dec;42(6):679-688.
150 Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms. Ann Transplant. 2016 Aug 9;21:491-9.
151 Conversion from Prograf to Advagraf in adolescents with stable liver transplants: comparative pharmacokinetics and 1-year follow-up. Liver Transpl. 2013 Oct;19(10):1151-8.
152 The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population. PLoS One. 2017 Mar 30;12(3):e0174511.
153 Association of ABCB1 C3435T polymorphism with phenobarbital resistance in Thai patients with epilepsy. J Clin Pharm Ther. 2015 Jun;40(3):315-9.
154 Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica. 2013 Feb;98(2):193-200.
155 ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis. Pharmacogenomics J. 2015 Apr;15(2):127-34.
156 Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients. Int J Clin Pharmacol Ther. 2014 Sep;52(9):746-55.
157 Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. Pharmacogenomics J. 2016 Feb;16(1):47-53.
158 Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010 Oct 16;376(9749):1320-8.
159 Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer. 2006 May 1;118(9):2195-201.
160 Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. Pharmacogenomics J. 2012 Apr;12(2):111-8.
161 Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Transplant Proc. 2010 Nov;42(9):3455-8.
162 The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther. 2015 Sep;53(9):728-36.
163 The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients. J Hum Genet. 2015 May;60(5):273-6.
164 Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant. Pharmacogenomics J. 2018 Jan;18(1):180-186.
165 Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms. Transplant Proc. 2017 Jul - Aug;49(6):1492-1498.
166 Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia. J Acquir Immune Defic Syndr. 2015 May 1;69(1):e36-7.
167 Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy. Clin Transplant. 2017 Jun;31(6).
168 Sex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A5*3/*3. Biochem Genet. 2017 Jun;55(3):268-277.
169 The Influence of C3435T Polymorphism of the ABCB1 Gene on Genetic Susceptibility to Depression and Treatment Response in Polish Population - Preliminary Report. Int J Med Sci. 2015 Nov 20;12(12):974-9.
170 CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Ther Drug Monit. 2010 Oct;32(5):573-8.
171 The influence of ABCB1 polymorphism C3435T on the pharmacokinetics of silibinin. J Clin Pharm Ther. 2015 Dec;40(6):685-8.
172 Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study. PLoS One. 2013 Sep 25;8(9):e75359.
173 Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One. 2012;7(6):e38150.
174 Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003 Apr 10;348(15):1442-8.
175 Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene. 2015 Mar 10;558(2):200-7.
176 Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Thromb Res. 2013 Jul;132(1):81-7.
177 Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness. Medicina (Kaunas). 2014;50(1):19-27.
178 Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Pharmacogenet Genomics. 2012 Dec;22(12):887-90.
179 Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia. J Clin Pharm Ther. 2016 Oct;41(5):546-51.
180 A donor and recipient candidate gene association study of allograft loss in renal transplant recipients receiving a tacrolimus-based regimen. Am J Transplant. 2018 Dec;18(12):2905-2913.
181 The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis. Pharmacogenet Genomics. 2012 Aug;22(8):642-5.
182 Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation. Int J Mol Sci. 2015 Aug 25;16(9):20168-82.
183 Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017 Feb;15(2):273-283.
184 Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients. Eur Rev Med Pharmacol Sci. 2016 Jun;20(11):2460-7.
185 Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2014 Aug;24(8):387-96.
186 The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma. Sci Rep. 2016 Feb 2;6:20089.
187 Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients. Transplantation. 2012 Nov 15;94(9):971-7.
188 Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther. 2011 Oct;90(4):561-7.
189 Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015 Apr;15(2):109-18.
190 Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis. 2011 Jan 15;203(2):246-57.
191 Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. Pharmacotherapy. 2017 Sep;37(9):1073-1080.
192 CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat. 2012 Jul;134(1):401-10.
193 Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics. 2010 Sep;11(9):1223-34.
194 Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug. Br J Clin Pharmacol. 2018 May;84(5):997-1005.
195 Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach. AAPS J. 2014 May;16(3):379-91.
196 Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation. Transplant Proc. 2013 Jan-Feb;45(1):137-41.
197 Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function. Exp Ther Med. 2015 Sep;10(3):1149-1156.
198 ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients. J Clin Pharmacol. 2013 Dec;53(12):1286-93.
199 Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics. 2011 Dec;12(12):1641-52.
200 ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis. J Gastroenterol Hepatol. 2017 Sep;32(9):1562-1569.
201 Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients. Exp Clin Transplant. 2015 Oct;13(5):441-8.
202 Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian J Hum Genet. 2011 May;17 Suppl 1:S32-40.
203 The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy Res. 2007 Feb;73(2):192-8.
204 Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One. 2011;6(10):e26091.
205 Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array. Eur J Clin Pharmacol. 2018 Oct;74(10):1291-1298.
206 Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure. 2006 Jan;15(1):67-72.
207 Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol. 2013 Jan;69(1):53-63.
208 Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation. Br J Clin Pharmacol. 2017 Apr;83(4):863-874.
209 Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters. Pharmacogenomics J. 2017 Jul;17(4):325-330.
210 ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. Eur J Clin Pharmacol. 2013 Mar;69(3):385-93.
211 ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients. Br J Clin Pharmacol. 2008 Aug;66(2):240-6.
212 ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther. 2011 Mar;89(3):422-8.
213 Role of SLCO1B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients. J Clin Pharmacol. 2015 Mar;55(3):261-8.
214 Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Invest New Drugs. 2004 Aug;22(3):285-9.
215 Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients. Pharmacol Res. 2016 Sep;111:877-884.
216 Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. Transplant Proc. 2009 Apr;41(3):840-2.
217 Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol. 2008 Apr;35(4):572-9.
218 Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation. Int J Clin Pract Suppl. 2015 May;(183):53-62.
219 Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. Cancer Chemother Pharmacol. 2017 Sep;80(3):653-659.
220 Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 Jul;16(4):274-81.
221 Correlation of MDR1 gene polymorphisms with anesthetic effect of sevoflurane-remifentanil following pediatric tonsillectomy. Medicine (Baltimore). 2017 Jun;96(24):e7002.
222 Correlation of MDR1 gene polymorphism with propofol combined with remifentanil anesthesia in pediatric tonsillectomy. Oncotarget. 2017 Dec 12;9(29):20294-20303.
223 Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013 Jan;14(1):35-45.
224 Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J. 2010 Oct;10(5):418-30.
225 Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation. Pharmacogenomics. 2015;16(9):971-9.
226 Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int. 2008 Sep;21(9):879-91.
227 Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics. 2011 Mar;12(3):365-77.
228 Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. Pharmacogenomics J. 2014 Oct;14(5):457-62.
229 ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population. BMC Genet. 2016 Jun 13;17(1):79.
230 Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol. 2006 Jun;61(6):706-15.
231 ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochem Pharmacol. 2009 Jan 1;77(1):66-75.
232 Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention. Eur J Clin Pharmacol. 2017 Sep;73(9):1085-1094.
233 Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008 Apr;99(4):816-23.
234 Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis. 2007 Jan;13(1):19-23.
235 Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study. Drug Alcohol Depend. 2014 Dec 1;145:185-93.
236 Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1310-5.
237 Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther. 2016 Jun;41(3):329-33.
238 Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta Oncol. 2014 Oct;53(10):1413-22.
239 mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):854-9.
240 Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome. BMC Pharmacol Toxicol. 2018 Apr 3;19(1):14.
241 Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients. Mol Biol Rep. 2015 Jan;42(1):105-17.
242 Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J Antimicrob Chemother. 2014 Nov;69(11):3061-6.
243 Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9.
244 Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008 Jan 24;57(2):203-9.
245 Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients. PLoS One. 2014 Nov 5;9(11):e111694.
246 The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis. 2006 Mar;185(1):97-107.
247 ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J. 2013 Aug;13(4):349-53.
248 Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study. J Psychiatr Res. 2016 Feb;73:86-95.
249 Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. Cancer Chemother Pharmacol. 2018 Jan;81(1):183-193.
250 Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma. Haematologica. 2015 May;100(5):e204-6.
251 Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. Pharmacol Res. 2016 Sep;111:501-508.
252 Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. Pharmacogenomics J. 2018 May 22;18(3):460-466.
253 Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013 Aug;60(8):1375-81.
254 Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012 May 1;30(13):1422-8.
255 ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients. Pharmacogenomics. 2013 Nov;14(14):1723-30.
256 Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. PLoS One. 2013 Oct 7;8(10):e76984.
257 Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. J Clin Psychopharmacol. 2012 Aug;32(4):441-8.
258 Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics. 2018 Feb;19(3):175-184.
259 CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation. Basic Clin Pharmacol Toxicol. 2018 Sep;123(3):320-326.
260 Opioid-induced respiratory depression: ABCB1 transporter pharmacogenetics. Pharmacogenomics J. 2015 Apr;15(2):119-26.
261 CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure. Pharmacogenomics. 2014 Aug;15(11):1423-35.
262 Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. PLoS One. 2014 Jan 31;9(1):e86919.
263 Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. PLoS One. 2017 Sep 8;12(9):e0181316.
264 CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. Pharmacogenomics. 2016 Apr;17(6):603-13.
265 ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2018 Jan;18(1):35-42.
266 Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016 Aug;144:1-5.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.